A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDGL SEC filings page.
Madrigal Pharmaceuticals, Inc. (MDGL) reported $958.4M in revenue for fiscal year 2025, up 432.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue reached commercial scale, yet operating costs still exceeded sales, leaving the business cash-consuming and more debt-financed.
Revenue expanded from$180.1M in FY2024 to$958.4M in FY2025, a commercial step-change. Operating cash flow improved from an outflow of$455.6M to$189.6M , yet free cash flow remained negative; sales growth therefore improved cash absorption without making operations self-funding.
Operating margin improved
Long-term debt rose
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Madrigal Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Madrigal Pharmaceuticals, Inc. held $983.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $189.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Madrigal Pharmaceuticals, Inc. scores 73/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Madrigal Pharmaceuticals, Inc. scores 63/100 on it among other emerging companies.
Madrigal Pharmaceuticals, Inc. spent $388.5M on research and development in fiscal year 2025, which was 30.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Madrigal Pharmaceuticals, Inc. scores 63/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Madrigal Pharmaceuticals, Inc. scores 95/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Madrigal Pharmaceuticals, Inc. scores 70/100 on it among other emerging companies.
Madrigal Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $983.6M at the end of fiscal year 2025, against $656.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Madrigal Pharmaceuticals, Inc. scores 70/100 among other emerging companies.
Madrigal Pharmaceuticals, Inc. scores 6.59, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $8.8B against total liabilities of $656.9M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Madrigal Pharmaceuticals, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Madrigal Pharmaceuticals, Inc. reported a net loss of $288.3M while operations used $189.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Madrigal Pharmaceuticals, Inc. reported an operating loss of $300.1M against $22.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Madrigal Pharmaceuticals, Inc. generated $431.3M in revenue in Q3 2026. This represents an increase of 50.1% from the same quarter a year earlier. Against the prior quarter it is up 18.4%.
Madrigal Pharmaceuticals, Inc.'s EBITDA was $56.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Madrigal Pharmaceuticals, Inc. reported $55.4M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Madrigal Pharmaceuticals, Inc. earned $1.83 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Madrigal Pharmaceuticals, Inc. generated $116.6M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 47.6% from the same quarter a year earlier. Against the prior quarter it is up 511.4%.
Madrigal Pharmaceuticals, Inc. held $514.6M in cash against $341.3M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Madrigal Pharmaceuticals, Inc.'s operating margin was 13.0% in Q3 2026, reflecting core business profitability. This is up 52.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 28.4 percentage points.
Madrigal Pharmaceuticals, Inc.'s net profit margin was 12.9% in Q3 2026, showing the share of revenue converted to profit. This is up 52.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 28.8 percentage points.
Madrigal Pharmaceuticals, Inc.'s quarterly ROE was 8.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 27.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 19.9 percentage points.
Not reported for Q3 2026.
Capital Allocation
Madrigal Pharmaceuticals, Inc. invested $71.8M in research and development in Q3 2026. This represents a decrease of 58.8% from the same quarter a year earlier. Against the prior quarter it is down 21.3%.
Madrigal Pharmaceuticals, Inc. invested $3.9M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 358.3% from the same quarter a year earlier. Against the prior quarter it is down 7.6%.
Not reported for Q3 2026.
MDGL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $431.3M+50.1% | $364.3M+71.2% | $311.3M+126.8% | $321.1M+210.8% | $287.3M+362.0% | $212.8M+1353.8% | $137.3Mn/m | $103.3Mn/m |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $4.5Mn/m | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | $132.7Mn/m | N/A |
| R&D Expenses | $71.8M-58.8% | $91.2M+68.6% | $108.7M+146.1% | $116.3M+353.3% | $174.0M+153.1% | $54.1M-23.9% | $44.2M-38.0% | $25.6M-63.7% |
| SG&A Expenses | $265.7M+27.1% | $289.4M+47.0% | $268.5M+60.0% | $240.0M+69.9% | $209.1M+94.4% | $196.9M+86.7% | $167.9M+107.8% | $141.2M+203.5% |
| Operating Income | $56.0Mn/m | -$56.3Mn/m | -$92.7Mn/m | -$59.6Mn/m | -$114.0Mn/m | -$47.2Mn/m | -$79.3Mn/m | -$67.0Mn/m |
| EBITDA | $56.4Mn/m | -$55.9Mn/m | -$92.3Mn/m | -$59.2Mn/m | -$113.6Mn/m | -$46.8Mn/m | -$78.9Mn/m | -$66.6Mn/m |
| Interest Expense | $8.1M+8.3% | $7.9M+143.3% | $7.8M+137.2% | $8.3M+137.2% | $7.5M+102.5% | $3.3M-10.7% | $3.3M-14.1% | $3.5M-11.9% |
| Net Income | $55.4Mn/m | -$57.9Mn/m | -$94.4Mn/m | -$58.6Mn/m | -$114.2Mn/m | -$42.3Mn/m | -$73.2Mn/m | -$59.4Mn/m |
| EPS (Basic) | $1.90n/m | -$1.99n/m | -$3.25n/m | -$2.03n/m | -$4.01n/m | -$1.50n/m | -$2.61n/m | -$2.59n/m |
| EPS (Diluted) | $1.83n/m | -$1.99n/m | -$3.25n/m | -$2.03n/m | -$4.01n/m | -$1.50n/m | -$2.61n/m | -$2.59n/m |
| Diluted Shares (Avg) | 30M+6.3% | 29M+3.2% | 29M+3.4% | N/A | 29M+31.1% | 28M+31.9% | 28M+40.4% | N/A |
Not reported in any period shown, so not listed: Income Tax.
MDGL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+5.3% | $1.2B+22.6% | $1.2B+23.1% | $1.3B+20.9% | $1.4B+26.9% | $1.0B-7.7% | $996.6M-7.9% | $1.0B+62.7% |
| Current Assets | $1.4B+3.0% | $1.2B+19.5% | $1.2B+19.7% | $1.2B+20.6% | $1.3B+26.6% | $1.0B-8.1% | $988.0M-8.0% | $1.0B+62.1% |
| Cash & Equivalents | $514.6M+74.0% | $292.7M+57.2% | $227.0M+23.6% | $198.7M+98.7% | $295.7M+27.1% | $186.2M-62.4% | $183.6M-70.5% | $100.0M+0.1% |
| Short-Term Investments | $446.3M-45.2% | $546.0M-10.6% | $585.7M-11.2% | $784.9M-5.0% | $814.1M+6.3% | $610.8M+8.5% | $659.4M+51.1% | $826.2M+54.7% |
| Inventory | $122.6M+76.9% | $99.4M+56.5% | $112.1M+102.9% | $74.8M+119.7% | $69.3M+695.4% | $63.5M+797.9% | $55.2M+6368.5% | $34.1Mn/m |
| Accounts Receivable | $227.4M+100.7% | $192.3M+142.7% | $187.4M+205.0% | $134.5M+149.9% | $113.3M+271.9% | $79.2M+1048.4% | $61.4M | $53.8Mn/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $807.4M+9.6% | $720.9M+125.7% | $683.9M+139.1% | $656.9M+128.2% | $736.7M+148.8% | $319.4M+31.6% | $286.0M+23.5% | $287.9M+22.4% |
| Current Liabilities | $454.2M+16.1% | $374.2M+90.4% | $338.3M+102.3% | $310.3M+83.3% | $391.4M+120.1% | $196.5M+57.0% | $167.2M+46.3% | $169.3M+42.8% |
| Non-Current Liabilities | $353.2M+2.3% | $346.7M+182.1% | $345.6M+191.0% | $346.6M+192.3% | $345.3M+192.0% | $122.9M+4.6% | $118.8M+1.3% | $118.6M+1.6% |
| Long-Term Debt | $341.3M+0.4% | $340.8M+187.9% | $340.3M+188.4% | $339.9M+189.1% | $339.8M+190.2% | $118.4M+1.5% | $118.0M+1.6% | $117.6M+1.8% |
| Total Equity | $626.9M+0.2% | $523.7M-24.7% | $543.5M-23.5% | $602.7M-20.1% | $625.7M-19.5% | $696.0M-18.8% | $710.6M-16.5% | $754.4M+86.1% |
| Retained Earnings | -$2.2Bn/m | -$2.2Bn/m | -$2.2Bn/m | -$2.1Bn/m | -$2.0Bn/m | -$1.9Bn/m | -$1.9Bn/m | -$1.8Bn/m |
Not reported in any period shown, so not listed: Goodwill.
MDGL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $120.6M+51.0% | $23.3Mn/m | -$167.4Mn/m | -$133.5Mn/m | $79.8Mn/m | -$47.1Mn/m | -$88.9Mn/m | -$104.5Mn/m |
| Depreciation & Amortization | $391K+9.2% | $381K+1.1% | $386K+1.8% | $392K+8.0% | $358K+20.1% | $377K+41.2% | $379K+125.6% | $363K+155.6% |
| Stock-Based Compensation | $38.9M+48.4% | $35.4M+40.6% | $34.0M+62.5% | N/A | $26.3M+46.7% | $25.2M+3.1% | $20.9M+5.2% | N/A |
| Capital Expenditures | $3.9M+358.3% | $4.3Mn/m | $3.8Mn/m | N/A | $857K+10.0% | $0-100.0% | $0-100.0% | $195K-81.2% |
| Free Cash Flow | $116.6M+47.6% | $19.1Mn/m | -$171.3Mn/m | N/A | $79.0Mn/m | -$47.1Mn/m | -$88.9Mn/m | -$104.7Mn/m |
| Investing Cash Flow | $93.8Mn/m | $34.2M-28.5% | $192.2M+17.3% | $27.6Mn/m | -$207.0Mn/m | $47.9Mn/m | $163.9M+67.1% | -$48.0Mn/m |
| Financing Cash Flow | $10.0M-95.8% | $3.1M+78.7% | $2.3M-73.0% | $9.0M-54.7% | $236.6M+3071.4% | $1.7M-98.7% | $8.6M-98.5% | $19.8M-95.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MDGL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 96.7% | N/A |
| Operating Margin | 13.0%+52.7pp | -15.5%+6.7pp | -29.8%+28.0pp | -18.6%+46.3pp | -39.7% | -22.2% | -57.8% | -64.8% |
| Net Margin | 12.9%+52.6pp | -15.9%+4.0pp | -30.3%+23.0pp | -18.2%+39.3pp | -39.8% | -19.9% | -53.4% | -57.5% |
| Return on Equity | 8.8%+27.1pp | -11.1%-5.0pp | -17.4%-7.1pp | -9.7%-1.8pp | -18.3%-4.5pp | -6.1%+11.7pp | -10.3%+7.0pp | -7.9%+19.8pp |
| Return on Assets | 3.9%+12.3pp | -4.7%-0.5pp | -7.7%-0.3pp | -4.7%+1.1pp | -8.4%+1.6pp | -4.2%+9.7pp | -7.3%+6.3pp | -5.7%+11.8pp |
| Current Ratio | 3.05-0.4x | 3.20-1.9x | 3.50-2.4x | 4.01-2.1x | 3.44-2.5x | 5.11-3.6x | 5.91-3.5x | 6.10+0.7x |
| Debt-to-Equity | 0.540.0x | 0.65+0.5x | 0.63+0.5x | 0.56+0.4x | 0.54+0.4x | 0.170.0x | 0.170.0x | 0.16-0.1x |
| Liabilities-to-Equity | 1.29+0.1x | 1.38+0.9x | 1.26+0.9x | 1.09+0.7x | 1.18+0.8x | 0.46+0.2x | 0.40+0.1x | 0.38-0.2x |
| Asset Turnover | 0.30+0.1x | 0.29+0.1x | 0.25+0.1x | 0.25+0.2x | 0.21+0.2x | 0.21+0.2x | 0.14+0.1x | 0.10+0.1x |
| FCF Margin | 27.0%-0.5pp | 5.2%+27.3pp | -55.0%+9.8pp | N/A | 27.5% | -22.1% | -64.8% | -101.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. MDGL | FY2025 | $958.4M | -$288.3M | -30.1% | $8.8B | 72/100 |
| Summit Therapeutics Inc. SMMT | FY2025 | N/A | -$1.1B | N/A | $8.0B | — |
| TG Therapeutics, Inc. TGTX | FY2025 | $616.3M | $447.2M | 72.6% | $9.6B | 61/100 |
| Krystal Biotech, Inc. KRYS | FY2025 | $389.1M | $204.8M | 52.6% | $9.2B | 61/100 |
| Kymera Therapeutics, Inc. KYMR | FY2025 | $39.2M | -$311.4M | N/A | $9.8B | 58/100 |
| Spyre Therapeutics, Inc. SYRE | FY2025 | $0 | -$155.2M | N/A | $8.9B | — |
Where Madrigal Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Madrigal Pharmaceuticals, Inc. (MDGL) reported $958.4M in total revenue for fiscal year 2025. This represents a 432.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Madrigal Pharmaceuticals, Inc. (MDGL) revenue grew by 432.1% year-over-year, from $180.1M to $958.4M in fiscal year 2025.
No, Madrigal Pharmaceuticals, Inc. (MDGL) reported a net loss of $288.3M in fiscal year 2025, with a net profit margin of -30.1%.
Madrigal Pharmaceuticals, Inc. (MDGL) had EBITDA of -$298.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Madrigal Pharmaceuticals, Inc. (MDGL) had $198.7M in cash and equivalents against $339.9M in long-term debt.
Madrigal Pharmaceuticals, Inc. (MDGL) had an operating margin of -31.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Madrigal Pharmaceuticals, Inc. (MDGL) had a net profit margin of -30.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Madrigal Pharmaceuticals, Inc. (MDGL) has a return on equity of -47.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Madrigal Pharmaceuticals, Inc. (MDGL) recorded an outflow of $190.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Madrigal Pharmaceuticals, Inc. (MDGL) recorded an outflow of $189.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Madrigal Pharmaceuticals, Inc. (MDGL) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
Madrigal Pharmaceuticals, Inc. (MDGL) invested $467K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Madrigal Pharmaceuticals, Inc. (MDGL) invested $388.5M in research and development during fiscal year 2025.
Madrigal Pharmaceuticals, Inc. (MDGL) had a current ratio of 4.01 as of fiscal year 2025, which is generally considered healthy.
Madrigal Pharmaceuticals, Inc. (MDGL) had a debt-to-equity ratio of 0.56 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Madrigal Pharmaceuticals, Inc. (MDGL) had a liabilities-to-equity ratio of 1.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Madrigal Pharmaceuticals, Inc. (MDGL) had a return on assets of -22.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Madrigal Pharmaceuticals, Inc. (MDGL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $8.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Madrigal Pharmaceuticals, Inc. (MDGL) trades at 6.2x sales, its market capitalization divided by $1.4B revenue, trailing 12 months to September 30, 2026. The market capitalization is $8.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Madrigal Pharmaceuticals, Inc. (MDGL) held $983.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $189.6M over that year. Dividing the one by the other, the reported balance equals about 62 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Madrigal Pharmaceuticals, Inc. (MDGL) has an Altman Z-Score of 6.59, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Madrigal Pharmaceuticals, Inc. (MDGL) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Madrigal Pharmaceuticals, Inc. (MDGL) reported a net loss of $288.3M while operations used $189.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Madrigal Pharmaceuticals, Inc. (MDGL) reported an operating loss of $300.1M against $22.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Madrigal Pharmaceuticals, Inc. (MDGL) scores 72 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.